EA201501137A1 - Биомаркеры генной экспрессии и их использование для диагностического и прогностического применения у пациентов, потенциально нуждающихся в лечении ингибитором hdac - Google Patents

Биомаркеры генной экспрессии и их использование для диагностического и прогностического применения у пациентов, потенциально нуждающихся в лечении ингибитором hdac

Info

Publication number
EA201501137A1
EA201501137A1 EA201501137A EA201501137A EA201501137A1 EA 201501137 A1 EA201501137 A1 EA 201501137A1 EA 201501137 A EA201501137 A EA 201501137A EA 201501137 A EA201501137 A EA 201501137A EA 201501137 A1 EA201501137 A1 EA 201501137A1
Authority
EA
Eurasian Patent Office
Prior art keywords
biomarkers
hdac inhibitor
diagnostic
gene expression
potentially treated
Prior art date
Application number
EA201501137A
Other languages
English (en)
Inventor
Томас Херц
Хелла Кольхоф
Роберт Добльхофер
Мартин Эльмлингер
Ханс-Петер Хофманн
Айке Штауб
Астрид Циммерманн
Томас Майер
Фолькер Гекелер
Марина Молленхауер-Тайн
Тимо Виттенбергер
Маркус Бём
Томас Беккерс
Original Assignee
4Ск Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Ск Аг filed Critical 4Ск Аг
Publication of EA201501137A1 publication Critical patent/EA201501137A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C12Q1/682—Signal amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G01N2333/98—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

Настоящее изобретение относится к применению одного или нескольких генов, выбранных из группы, включающей ZFP64, DPP3, CCDC43, HIST2H4A/B, KDELC2 и MICALL1, в качестве биомаркеров для лечения ингибитором HDAC. Экспрессию и/или изменение вышеупомянутых генов предпочтительно определяли с помощью соответствующей мРНК или одного или нескольких белков, экспрессируемых вышеупомянутыми генами.
EA201501137A 2013-05-24 2014-05-22 Биомаркеры генной экспрессии и их использование для диагностического и прогностического применения у пациентов, потенциально нуждающихся в лечении ингибитором hdac EA201501137A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361827201P 2013-05-24 2013-05-24
US201361865712P 2013-08-14 2013-08-14
US201461935914P 2014-02-05 2014-02-05
PCT/EP2014/060532 WO2014187894A1 (en) 2013-05-24 2014-05-22 Gene expression biomarkers and their use for diagnostic and prognostic application in patients potentially in need of hdac inhibitor treatment

Publications (1)

Publication Number Publication Date
EA201501137A1 true EA201501137A1 (ru) 2016-06-30

Family

ID=50771295

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201501137A EA201501137A1 (ru) 2013-05-24 2014-05-22 Биомаркеры генной экспрессии и их использование для диагностического и прогностического применения у пациентов, потенциально нуждающихся в лечении ингибитором hdac

Country Status (12)

Country Link
US (1) US20160215348A1 (ru)
EP (1) EP3004377A1 (ru)
JP (1) JP2016521543A (ru)
KR (1) KR20160010498A (ru)
CN (1) CN105408498A (ru)
AU (1) AU2014270380A1 (ru)
BR (1) BR112015028997A2 (ru)
CA (1) CA2912973A1 (ru)
EA (1) EA201501137A1 (ru)
HK (1) HK1223129A1 (ru)
MX (1) MX2015016114A (ru)
WO (1) WO2014187894A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017034234A1 (ko) * 2015-08-21 2017-03-02 서울대학교 산학협력단 Hdac 억제제 내성을 갖는 암 치료용 복합제제
CN110412268A (zh) * 2018-04-27 2019-11-05 刘晓健 诊断经典霍奇金淋巴瘤的结外累犯的标志物及其应用
CN112691199A (zh) * 2021-01-26 2021-04-23 冠科生物技术(苏州)有限公司 一种预测病患对抑制剂反应的标志物及其使用方法
CN115267165A (zh) * 2022-08-15 2022-11-01 海仕兰(上海)生物科技有限公司 一种悬浮芯片系统及其应用以及基于悬浮芯片系统对肿瘤伴随诊断因子检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859502B2 (en) * 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
CN104056270B (zh) * 2013-02-21 2018-11-09 中国人民解放军军事医学科学院野战输血研究所 用于制备多器官损伤救治药物的组蛋白去乙酰化酶抑制剂

Also Published As

Publication number Publication date
JP2016521543A (ja) 2016-07-25
EP3004377A1 (en) 2016-04-13
HK1223129A1 (zh) 2017-07-21
CA2912973A1 (en) 2014-11-27
KR20160010498A (ko) 2016-01-27
AU2014270380A1 (en) 2015-11-19
CN105408498A (zh) 2016-03-16
MX2015016114A (es) 2016-07-21
BR112015028997A2 (pt) 2017-10-24
US20160215348A1 (en) 2016-07-28
WO2014187894A1 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
EA201890013A1 (ru) Способы получения tcr гамма дельтат-клеток
EA201790413A1 (ru) Антитела против tigit
EA201690965A1 (ru) Транскрипционный рнк-вектор и его применения
EA201692370A1 (ru) КОМПОЗИЦИИ иРНК АНГИОТЕНЗИНОГЕНА (AGT) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ
EA201592074A1 (ru) Композиции и способы изменения сигнальной системы вторичного мессенджера
EA201690087A1 (ru) Новые квиназолиноны как ингибиторы бромодомена
EA201492101A1 (ru) Антитела против fcrn
EA201591707A1 (ru) КОМПОЗИЦИИ иРНК КОМПОНЕНТА КОМПЛЕМЕНТА C5 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201492137A1 (ru) Антитела к cd33 и их применение в лечении рака
EA201491541A1 (ru) АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αvβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
EA201591764A1 (ru) Варианты тканевого ингибитора металлопротеиназ третьего типа (timp-3), композиции и способы
EA201391329A1 (ru) Модуляция экспрессии трансдуктора сигнала и активатора транскрипции 3 (stat3)
EA201600252A1 (ru) Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования
EA201791424A1 (ru) Получение белка
EA201391312A1 (ru) Антитело к человеческому тканевому фактору и его применение
CY1122233T1 (el) Μεθοδος για την προβλεψη του αποτελεσμaτος μιας θεραπειας με αφλιβερσεπτη ενος ασθενους με υποψια οτι πασχει απο καρκινο
EA201691541A1 (ru) Новые анти-baff антитела
EA201690213A1 (ru) Композиции и способ лечения связанных с комплементом состояний
EA201591514A1 (ru) Антитела к пан-хемокинам подсемейства elrcxc
EA201690503A1 (ru) Антитела
EA201792096A3 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
EA201690599A1 (ru) Конъюгированные антитела против ly75 для лечения рака
EA201501137A1 (ru) Биомаркеры генной экспрессии и их использование для диагностического и прогностического применения у пациентов, потенциально нуждающихся в лечении ингибитором hdac